The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday ... vaccine ...

Novavax said the European Commission has granted ... Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech ...

Novavax’s COVID-19 vaccine produced higher levels of neutralising antibodies than produced by recovered patients in an early trial, paving the way for a phase 3 trial and potential approval by ...

Neurogene shares tumbled 35% last night after it disclosed that a pediatric patient with Rett syndrome experienced a severe ...

guidance to use the latest selected strain and the guidance from the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and World Heal Novavax, Inc. (Nasdaq: NVAX), a global ...

Novavax’s phase 3 trial in the US is still ongoing with 30,000 participants, but the company hope data already reported from the UK trial will be enough to convince the FDA to approve.

However, recent news represents a setback ... though, that Novavax isn't depending solely on this candidate. It recently launched its latest coronavirus vaccine for the current season.

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

Summer's rise in COVID-19 cases led to the approval of updated versions of vaccinations targeting recent strains for the 2024 ...

'Nothing short of alarming': The full-time workers being priced out of the rental market ...